Yasuaki Sagara

6.8k citations

109 papers · 2.9k indexed · 2 hit papers · h-index 25

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis

Papers in

Cancer Research 58
- Breast Cancer Treatment Studies 50
Oncology 70
- HER2/EGFR in Cancer Research 32
- Cancer Treatment and Pharmacology 19
- Global Cancer Incidence and Screening 11

Co-authors: Mehra Golshan Stephanie M. Wong Fatih Aydoğan William T. Barry Hiroji Iwata Rachel A. Freedman Junji Tsurutani Shanu Modi
Journals: Breast Cancer (24 papers)Breast Cancer Research and Treatment (14 papers)Journal of Clinical Oncology (9 papers)Annals of Surgical Oncology (6 papers)Cancer Research (5 papers)
Partner nations: Japan United States Türkiye

In The Last Decade

Yasuaki Sagara

99 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study 2020 · 551 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Journal of Clinical Oncology
2019 The Lancet Oncology

Peers

Countries citing papers authored by Yasuaki Sagara

Since Specialization

Citations

This map shows the geographic impact of Yasuaki Sagara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuaki Sagara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuaki Sagara more than expected).

Fields of papers citing papers by Yasuaki Sagara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuaki Sagara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuaki Sagara. The network helps show where Yasuaki Sagara may publish in the future.

Co-authors

The 25 scholars most cited alongside Yasuaki Sagara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yasuaki Sagara Line = papers co-authored together Yasuaki Sagara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes Clinical Breast Cancer ·Reiki Nishimura, M K Ranade, Tetsuhiko Taira, Toshiko Miyaki, II Sun Kim, Daisuke Yotsumoto, 林颐, Harold Van Der Werff, Hanne Seelbacher-Holzmann, Aqila Salmaagista, Shinichi Baba, Yasuyo Ohi, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara	2024	2
2	2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan Breast Cancer ·Yasuaki Sagara, Hiraku Kumamaru, Naoki Niikura, Minoru Miyashita, Takaaki Konishi, Takayuki Iwamoto, Naoko Sanuki, 弘泰西澤, Masayuki Nagahashi, Naoki Hayashi, Masayuki Yoshida, Naoko Kinukawa, Chie Watanabe, Masakazu Toi, Shigehira Saji	2024	3
3	Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma Breast Cancer Research and Treatment ·Saki Nakagawa, Minoru Miyashita, Ichiro Maeda, C José Cañas, Hiroshi Tada, Masakazu Amari, Yasuyuki Kojima, Koichiro Tsugawa, Yasuyo Ohi, Yasuaki Sagara, George Wei-Shu Hou, Akiko Ebata, Narumi Harada‐Shoji, Takashi Suzuki, Makoto Nakanishi, Tomohiko Ohta, Takanori Ishida	2024	2
4	Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry Breast Cancer ·Takayuki Iwamoto, Hiraku Kumamaru, Naoki Niikura, Yasuaki Sagara, Minoru Miyashita, Takaaki Konishi, Naoko Sanuki, 弘泰西澤, Masayuki Nagahashi, Naoki Hayashi, Masayuki Yoshida, Chie Watanabe, Naoko Kinukawa, Masakazu Toi, Shigehira Saji	2024	3
5	Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives Breast Cancer ·Sara. L Villagrá Sobrino, W. Benjamin Goodman, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, D. Lenica, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Shinji Ohno	2023	4
6	Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer Breast Cancer Research and Treatment ·Shinsuke Sasada, Naoto Kondo, Hiroya Hashimoto, Yuko Takahashi, C. Wang, Kumiko Kida, Yasuaki Sagara, Takayuki Ueno, Keisei Anan, Akihiko Suto, Chizuko Kanbayashi, Mina Takahashi, Rikiya Nakamura, Toshiyuki Ishiba, Michiko Tsuneizumi, Seiichiro Nishimura, Yoichi Naito, Fumikata Hara, Tadahiko Shien, Hiroji Iwata	2023	2
7	Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer Breast Cancer ·M K Ranade, Masahiro Kashiwaba, Urvashi Andotra, Harold Van Der Werff, 林颐, II Sun Kim, Yoshiaki Rai, Tetsuhiko Taira, Yoshiaki Sagara, Yasuyo Ohi, 洋一森口, Young-Won Lee, Sae Byul Lee, Gyungyub Gong, Young Kee Shin, Mi Kwon, Yasuaki Sagara	2023	1
8	Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B) The Breast ·Hiroko Masuda, Yuko Tanabe, Zhehong JIN, Koji Matsumoto, Akihiko Shimomura, 刘思辰, Yasuo Miyoshi, Masato Takahashi, Yasuaki Sagara, Shinya Tokunaga, Tsutomu Iwasa, Naoki Niikura, Kenichi Yoshimura, Toshimi Takano, Junji Tsurutani	2023	13
9	Evaluation of RASSF1A methylation in the lysate of sentinel lymph nodes for detecting breast cancer metastasis: A diagnostic accuracy study Oncology Letters ·S Sall, John S. Berens, Naofumi Kagara, Yasuyo Ohi, Hanne Seelbacher-Holzmann, Kaori Abe, Tetsuhiro Yoshinami, N.V. Bondareva, Tomohiro Miyake, Tomonori Tanei, Masafumi Shimoda, Yasuaki Sagara, Kenzo Shimazu	2023	3
10	Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer Clinical Pharmacology & Therapeutics ·Akihiko Shimomura, Toshimi Takano, Shunji Takahashi, Yasuaki Sagara, Junichiro Watanabe, Eriko Tokunaga, Tetsu Shinkai, Takahiro Kamio, Z. Mao, Emi Kamiyama, Yoshihiko Fujisaki, E Altuna, Toshinari Yamashita	2022	11
11	Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study British Journal of Cancer ·Hirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, Yasuo Hozumi, Tomomi Fujisawa, Shozo Ohsumi, Hiromitsu Akabane, Reiki Nishimura, Tsutomu Takashima, Young‐Jin Park, Yasuaki Sagara, Tatsuya Toyama, Shigeru Imoto, Toshiro Mizuno, Satoshi Yamashita, Satoshi Fujii, Yukari Uemura	2020	13
12	The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial Surgical Oncology ·Takeshi Yamaguchi, Yasuo Hozumi, Yasuaki Sagara, Masato Takahashi, Yu-Shan Song, Tomomi Fujisawa, 氏貴伊藤, Hiromitsu Akabane, Reiki Nishimura, Makiko Mieno, Hirofumi Mukai	2020	5
13	First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis Breast Cancer ·Tatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, Tatsuya Toyama, Hiroji Iwata	2020	12
14	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study The Lancet Oncology ·Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E. Krop, Charles H. Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi K. Murthy, Rebecca Redman, Takahiro Jikoh, Caleb Lee, Masahiro Sugihara, Javad Shahidi, Antoine Yver, Shanu Modi Hit paper breakdown →	2019	258
15	Maspin mRNA expression in sentinel lymph nodes predicts non‐SLN metastasis in breast cancer patients with SLN metastasis Histopathology ·Yoshihisa Umekita, Yasuyo Ohi, Norhayati Hassan, Masakazu Souda, Yasuaki Sagara, Shugo Tamada, Daisuke Yotsumoto, Akihide Tanimoto	2018	2
16	Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies Breast Cancer Research and Treatment ·Akira I. Hida, Yasuaki Sagara, Daisuke Yotsumoto, Shuichi Kanemitsu, Harold Van Der Werff, Shinichi Baba, Yoshiaki Rai, Yumi Oshiro, Kenjiro Aogi, Yoshiaki Sagara, Yasuyo Ohi	2016	50
17	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas Breast Cancer Research and Treatment ·万文坚 Wan Wenjian, Yasuhiro Miki, Minoru Miyashita, Shuko Hata, Inge Rahmawati, Hisashi Hirakawa, Yasuaki Sagara, Yoshiaki Rai, Yasuyo Ohi, Kentaro Tamaki, Takanori Ishida, Takashi Suzuki, M Wank, Hironobu Sasano	2016	8
18	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer Breast Cancer ·Hirofumi Mukai, Tomohiko Aihara, Yutaka Yamamoto, Masato Takahashi, Tatsuya Toyama, Yasuaki Sagara, Hiroshi Yamaguchi, Hiromitsu Akabane, Junji Tsurutani, Fumikata Hara, Tomomi Fujisawa, Naohito Yamamoto, Shozo Ohsumi	2014	12
19	Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer Diagnostic Pathology ·Yoshihisa Umekita, Yasuyo Ohi, Masakazu Souda, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara, Shugo Tamada, Akihide Tanimoto	2011	25
20	Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) ·Yoshiaki Rai, Yasuaki Sagara, M. Zunaid, Samir A. El-Tantawy, M. Rohani-Rad, Yoshiaki Sagara, P R Woodfield, Shinichi Baba, Y Matsuyama, Ilias Cheimariotis, Yoshiatsu Sagara	2008	0

About Yasuaki Sagara

Yasuaki Sagara is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Genetics, having authored 109 papers that have together received 2.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (50 papers), HER2/EGFR in Cancer Research (32 papers), Breast Lesions and Carcinomas (20 papers), Cancer Treatment and Pharmacology (19 papers), Advanced Breast Cancer Therapies (15 papers), Estrogen and related hormone effects (13 papers), Global Cancer Incidence and Screening (11 papers) and Breast Implant and Reconstruction (10 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.8k citations), Radiology, Nuclear Medicine and Imaging (669 citations), Pathology and Forensic Medicine (383 citations) and Pulmonary and Respiratory Medicine (656 citations). Yasuaki Sagara has collaborated with scholars based in Japan, United States and Türkiye. Frequent co-authors include Mehra Golshan, Stephanie M. Wong, Fatih Aydoğan, William T. Barry, Hiroji Iwata, Rachel A. Freedman, Junji Tsurutani, Shanu Modi, Ian E. Krop and Shunji Takahashi. Their work appears in journals such as Breast Cancer, Breast Cancer Research and Treatment, Journal of Clinical Oncology, Annals of Surgical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact